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BACKGROUND AND PURPOSE: The Tigertriever is a novel, radially adjustable, fully visible, stentriever that permits the operator to 
align radial expansion with target vessel diameters. This multicenter trial compared the Tigertriever’s effectiveness and safety 
compared with established stent retrievers.
METHODS: Single arm, prospective, multicenter trial comparing the Tigertriever to efficacy and safety performance goals derived 
from outcomes in 6 recent pivotal studies evaluating the Solitaire and Trevo stent-retriever devices with a lead-in and a main-
study phase. Patients were enrolled if they had acute ischemic stroke with National Institutes of Health Stroke Scale score ≥8 
due to large vessel occlusion within 8 hours of onset. The primary efficacy end point was successful reperfusion, defined as core 
laboratory-adjudicated modified Thrombolysis in Cerebral Ischemia score 2b-3 within 3 passes of the Tigertriever. The primary 
safety end point was a composite of 90-day all-cause mortality and symptomatic intracranial hemorrhage. Secondary efficacy 
end points included 3-month good clinical outcome (modified Rankin Scale score 0–2) and first-pass successful reperfusion.
RESULTS: Between May 2018 and March 2020, 160 patients (43 lead-in, 117 main phase) at 17 centers were enrolled and treated 
with the Tigertriever. The primary efficacy end point was achieved in 84.6% in the main-study phase group compared with the 63.4% 
performance goal and the 73.4% historical rate (noninferiority P<0.0001; superiority P<0.01). The first pass successful reperfusion 
rate was 57.8%. After all interventions, successful reperfusion (modified Thrombolysis in Cerebral Ischemia score ≥2b) was achieved 
in 95.7% and excellent reperfusion (modified Thrombolysis in Cerebral Ischemia score 2c-3) in 71.8%. The primary safety composite 
end point rate of mortality and symptomatic intracranial hemorrhage was 18.1% compared with the 30.4% performance goal and 
the 20.4% historical rate (noninferiority P=0.004; superiority P=0.57). Good clinical outcome was achieved in 58% at 90 days.
CONCLUSIONS: The Tigertriever device was shown to be highly effective and safe compared with Trevo and Solitaire devices to 
remove thrombus in patients with large-vessel occlusive stroke eligible for mechanical thrombectomy.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03474549.
GRAPHIC ABSTRACT: An online graphic abstract is available for this article.
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Based on convergent evidence from major clinical trials of reperfusion efficacy and improved clinical outcomes, endovascular thrombectomy with stent 
retrievers has become the standard of care for patients 
with large vessel occlusion ischemic strokes.1–8 A meta-
analysis of 5 randomized trials demonstrated the number 
needed to treat with thrombectomy is 1 in 2.6 to improve 
3-month global disability outcome by 1 or more levels on 
the modified Rankin Scale (mRS).9 However, while quite 
substantial, the benefits conveyed by first-generation 
stent retrievers are constrained by less than maximal 
reperfusion rates achieved with these devices. In pooled, 
individual participant data meta-analyses of the pivotal 
trials, failure to achieve successful reperfusion (modi-
fied Thrombolysis in Cerebral Ischemia [mTICI] 2b-3) 
occurred in 29% of patients and failure to achieve com-
plete reperfusion (mTICI 3) in 67%.9 Accordingly, devel-
oping additional endovascular thrombectomy devices 
with performance characteristics comparable or better 
than established stent retrievers is desirable.
The Tigertriever (Rapid Medical) is a novel operator-
adjustable stent retriever that affords the interventional-
ist incremental control over the radial diameter and radial 
force of the thrombectomy basket. The design is intended 
to facilitate alignment of the mesh with the anatomy of 
the occluded vessel and to increase internalization of the 
thrombus within the device, thereby facilitating retrieval 
and reducing downstream embolization (Figure 1A; Figure 
I in the Data Supplement). The device has had CE mark, 
the European Union certification indicating conformity with 
health, safety, and environmental protection, since 2016 
and has shown promising signals of efficacy and safety in 
preliminary case series reported by European centers.10–12
The TIGER trial (Treatment With Intent to Gener-
ate Endovascular Reperfusion) was a single-arm, mul-
ticenter, prospective study assessing the efficacy and 
safety of the Tiger-21 and Tiger-17 retrievers. The study 
employed an objective performance criterion, noninferi-
ority design, comparing efficacy and safety of the Tiger-
triever with performance goals derived from adjudicated 
outcomes in 6 completed prospective trials of 2 FDA-




The data that support the findings of this study are available from 
the corresponding author on reasonable request and with approval 
from the TIGER investigators. The primary TIGER Study hypoth-
esis was that the Tigertriever device would achieve successful 
reperfusion performance within 3 attempts would be superior 
to the performance goal established using Bayesian meta-anal-
ysis of 6 recent pivotal trials of the Solitaire and Trevo stent-
retriever devices—TREVO 2 (Thrombectomy Revascularization 
of Large Vessel Occlusions in Acute Ischemic Stroke),13 SWIFT 
(SOLITAIRE FR With the Intention for Thrombectomy),14 MR 
CLEAN (Multicenter Randomized Clinical Trial of Endovascular 
Treatment for Acute Ischemic Stroke in the Netherlands),1 
ESCAPE (Endovascular Treatment for Small Core and Anterior 
Circulation Proximal Occlusion With Emphasis on Minimizing 
CT to Recanalization Times),4 REVASCAT (Randomized Trial of 
Revascularization With Solitaire FR Device Versus Best Medical 
Therapy in the Treatment of Acute Stroke due to Anterior 
Circulation Large Vessel Occlusion Presenting Within Eight 
Hours of Symptom Onset),3 and SWIFT PRIME (Solitaire With the 
Intention for Thrombectomy as Primary Endovascular Treatment).2
The study was overseen by an executive committee, com-
posed of academic investigators, and an independent data 
and safety monitoring board (DSMB) (Table I in the Data 
Supplement). The DSMB consisted of an independent stroke 
neurologist and 2 independent neurointerventionalists, who did 
not enroll patients, and a biostatistician. At the level of individual 
events, the DSMB adjudicated all safety end points, includ-
ing hemorrhages and serious adverse events. At the level of 
aggregate study data, the DSMB acted in an expert supervisory 
capacity and monitored subject safety and the conduct of the 
study. Central readers at a core imaging laboratory assessed 
qualifying diagnostic catheter angiography to determine loca-
tion of the target occlusion, and rated reperfusion grades on 
angiograms obtained after every pass of the Tigertriever device, 
every pass of rescue therapy, and end of the procedure. The core 
laboratory imaging readers also assessed baseline and 24-hour 
post-procedure computed tomography (CT) or magnetic reso-
nance imaging scans to verify study entry criteria and determine 
the presence and type of any postprocedure intracranial hemor-
rhage. The sponsor, Rapid Medical, and its contracted Contract 
Research Organization (Genae Americas) were responsible for 
logistical operations, data management, and monitoring of the 
trial. The study protocol was approved by the institutional review 
board or ethics committee at each participating site.
Population and Participating Centers
All patients or their legally authorized representative provided 
written informed consent before enrollment. Patients aged 18 
Nonstandard Abbreviations and Acronyms
BGC balloon guide catheter
CT computed tomography
DSMB data and safety monitoring board
IQR interquartile range
IV tPA  intravenous tissue-type plasminogen 
activator
mRS modified Rankin Scale
mTICI  modified Thrombolysis in Cerebral 
Ischemia
NIHSS  National Institutes of Health Stroke 
Scale
PG performance goal
sICH symptomatic intracranial hemorrhage
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to 85 years were eligible for the study if they had acute isch-
emic stroke with new moderate-to-severe neurological deficits, 
angiographically confirmed occlusion in the intracranial internal 
carotid, middle cerebral (M1 or M2 segment), basilar, or verte-
bral artery, and could undergo endovascular therapy (at least 1 
Tigertriever deployment in the target artery) within 8 hours of 
last known well. Full study entry criteria are shown in the Data 
Supplement (Table II in the Data Supplement). Key inclusion cri-
teria included the following: prestroke mRS score ≤1; baseline 
National Institutes of Health Stroke Scale (NIHSS) score 8–29; 
Alberta Stroke Program Early CT Score 6–10 for CT-qualifying 
or diffusion restriction volume ≤50 mL for magnetic resonance 
imaging-qualifying anterior circulation cases; patient being 
either (1) eligible for, and received, IV tPA (intravenous tissue-
type plasminogen activator) within 3 hours of symptom onset 
or (2) ineligible for IV tPA treatment; and anticipated device 
deployment within 8 hours of last known well. Key exclusion 
criteria included stenosis or occlusion in the deployment site 
or in a proximal vessel that would prevent device access to the 
thrombus or require angioplasty or stenting to enable device 
access to the thrombus. The treatment start inclusion criterion 
of within 8 hours, rather than also 8 to 24 hours with advanced 
imaging selection, was selected as initial trial design discussions 
and review with the Food and Drug Administration occurred 
before the reporting of results of late window trials. Physicians 
were trained in the use of the device on a bench vascular model 
before any procedures were done. In addition, participating 
sites that had no experience with the Tigertriever device were 
required to first participate in a lead-in phase before partici-
pating in the main-study phase for primary end point analysis. 
During the lead-in phase, up to 4 patients per clinical site were 
enrolled. The lead-in phase was completed by the site either (1) 
achieving 2 successive successful reperfusions (mTICI 2b or 
higher) or (2) performing 4 cases. Patients enrolled in the lead-
in phase were consented, treated, and followed according to the 
clinical protocol, in the same manner as the main-study patients.
Procedure
Site of arterial access and anesthesia mode were based on 
operator preference at the enrolling center. The selection of 
guide catheter type (balloon guide catheter (BGC) versus non-
BGC) and use of an intermediate catheter was also at the dis-
cretion of the operator. After placement of the guide catheter 
in the target vessel, a roadmap was constructed and the micro-
catheter was navigated across the clot. The Tigertriever was 
deployed and the amount of expansion of the device was based 
on vessel diameter and clot length.
Two versions of the Tigertriever device were available: The 
standard version (Tigertriever) has a net length of 32 mm (unex-
panded form) and can expand up to 6 mm diameter, can be deliv-
ered through a microcatheter with an internal diameter of 0.021 
inches. And a smaller version (Tigertriever 17) has a net length 
of 23 mm (unexpanded form) and can be delivered through a 
microcatheter with an internal diameter of 0.017 inches. It can 
expand up to 3 mm diameter. The device deployment, dwell 
time, and number of expansions/deflations were based on 
the instructions for use. The first pass was required to be with 
the Tigertriever for inclusion in the trial. Up to 3 passes of the 
Tigertriever were permitted to achieve successful reperfusion 
(mTICI, 2b-3). For each pass, a new Tigertriever device was used 
and the total number of passes and devices used were recorded. 
After 3 attempts, rescue therapy could be used by the opera-
tor. Rescue therapy could consist of use of another mechanical 
thrombectomy device, angioplasty, intraarterial tPA, or intra-
cranial stenting at the discretion of the treating physician. The 
Tigertriever could not be used after a rescue attempt and for pri-
mary efficacy analysis when revascularization was unsuccessful 
after Tigertriever attempts it was considered a failure to achieve 
the end point. Imaging with CT or magnetic resonance imaging 
was obtained at 24 hours to assess for intracranial hemorrhage. 
Figure 1. Tigertriever device and chart of patient flow through 
study.
A, Tigertriever device including external handle for the operator to control 
the degree of expansion of the stent retriever. Fine wire mesh mounted 
on a flexible shaft. The design of the wire mesh (magnified view) is 
optimized to penetrate the clot and encapsulate it during retrieval. B, 
Patient screening, enrollment, treatment, and follow-up. ICH indicates 
intracranial hemorrhage; LVO, large vessel occlusion; mRS, modified 
Rankin Scale; and NIHSS, National Institutes of Health Stroke Scale.
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NIHSS scores were obtained at 24 hours, 48 hours, 4 days (or 
discharge if sooner), and 90 days; mRS scores were obtained at 
4 days (or discharge if sooner), 30 days, and 90 days.
Outcomes
Primary Efficacy End Point
The primary efficacy end point was successful reperfusion, 
defined as achieving mTICI 2b-3 within 3 passes with the 
Tigertriever without use of rescue therapy. All angiograms 
were interpreted by an experienced neurointerventional-
ist readers at the independent core imaging laboratory, who 
assigned scores using the mTICI scale.15 The core imaging 
laboratory mTICI ratings were used for assessment of the pri-
mary efficacy end point.
Primary Safety End Point
The primary safety end point was defined as the composite of 
all-cause mortality at 90±14 days and symptomatic intracranial 
hemorrhage (sICH) within 24 (18–36) hours from the study pro-
cedure. sICH was defined as any parenchymal hematoma type 2, 
remote intracerebral hemorrhage, subarachnoid hemorrhage, or 
intraventricular hemorrhage that is the predominant cause of an 
NIHSS deterioration of 4 or more points at 24 hours, as adjudi-
cated by the DSMB (modified Heidelberg Bleeding Classification 
criteria).16 The independent core imaging laboratory assessed 
all 24-hour CT/MR images and radiologically classified hem-
orrhages as hemorrhagic infarction types 1 or 2, parenchymal 
hematoma types 1 or 2, remote intracerebral hemorrhage, sub-
arachnoid hemorrhage, and intraventricular hemorrhage.
Secondary End Points
Prespecified secondary efficacy end points for the study were (1) 
good clinical outcome (mRS score 0–2 at 90 days; (2) first pass 
successful reperfusion (mTICI 2b-3); (3) health-related quality 
of life at 90 days, assessed with the EQ-5D2,17; and (4) granular 
level of disability at 90 days, assessed with the Academic Medical 
Center Linear Disability Score.18,19 Prespecified secondary safety 
end points were (1) asymptomatic intracranial hemorrhage within 
24 hours (18–36 hours) of procedure; (2) neurological dete-
rioration within 24 hours after procedure, defined as a NIHSS 
increase of 4 points or more; and (3) embolization to previously 
uninvolved vascular territories.
Statistical Analysis
The performance goal for the efficacy primary end point was 
defined as the incidence in the 6 trials cited below, minus 
a noninferiority statistical margin of 10%, the same clini-
cally relevant threshold employed in the registration trials of 
stent-retrievers, SWIFT and TREVO 2,9,13 therefore, giving a 
performance goal (PG) of 73.4%−10%=63.4%. The pooled 
incidence was derived from the following 6 studies: TREVO 
2, SWIFT,1 MR CLEAN, ESCAPE, REVASCAT, and SWIFT 
PRIME.1–4,9,13 For this efficacy end point, the primary nonin-
feriority hypothesis test was performed at an overall 2-sided 
alpha level of 0.05 using exact binomial methods, in which the 
lower confidence bound on the observed incidence of reper-
fusion is compared with the PG. If noninferiority was demon-
strated, superiority was then tested in a post hoc hierarchical 
manner. The study statistical design is shown graphically in 
Figure IIA in the Data Supplement.
The PG for safety primary end point was defined as the 
incidence in the 6 trials cited above, plus a statistical margin 
of 10%. Thus, the PG was 30.4% (18.2% mortality+2.2% 
sICH+10% noninferiority statistical margin). For primary safety, 
the hypothesis test was performed at an overall 2-sided alpha 
level of 0.05 using exact binomial methods, in which the upper 
confidence bound on the observed incidence of revasculariza-
tion is compared with the PG.
The primary study population was the main-study phase 
group. Sensitivity analysis was performed at regulatory request 
on the combined lead-in/main-study phase population). To 
evaluate Tigertriever device performance in vessels with of 
varied size, the study population was divided into 2 vessel 
diameter categories, ≥2 and <2 mm, and performance com-
pared across the groups.
RESULTS
Between May 2018 and March 2020, 1712 patients 
were preliminarily screened, 183 consented before angi-
ography, and 160 met angiographic and device access 
criteria for full study enrollment. Patients were enrolled at 
17 study centers (16 US centers—159 patients, 1 Israeli 
center—1 patient; Table I in the Data Supplement) and 
included 43 lead-in phase and 117 main-study phase 
patients. Figure 1B shows the screening, enrollment, 
treatment, and follow-up flow of the study population.
Patient baseline characteristics are shown for the main-
study phase and combined lead-in/main-study phase 
cohorts in Table 1 (Table III in the Data Supplement shows 
patient characteristics for the lead-in phase patients alone; 
Tables IV and V in the Data Supplement compare patient 
characteristics and outcomes in the current trial with those 
of the 6 trials contributing to the performance goal and 
the more recent ARISE II trial [Analysis of Revasculariza-
tion in Ischemic Stroke With EmboTrap]). In the main-study 
phase cohort, patient age was mean 65±15 years, 61.5% 
were men, and median baseline NIHSS 17 (interquartile 
range [IQR], 12–21). The median Alberta Stroke Program 
Early CT score was 9 (IQR, 8–10). Target occlusion loca-
tion was in the anterior circulation in 97.4% of patients, 
with the most common sites the M1 middle cerebral artery 
(57.3%) and intracranial internal carotid artery (20.5%). 
Time from last known normal to puncture was 172 min-
utes (IQR, 128–273), and a majority (65.8%) of patients 
received intravenous t-PA before thrombectomy. A BGC 
was used in 29.9% of the procedures (21.4% BGC alone 
and 8.5% BGC+regional aspiration).
Primary Efficacy End Point and Reperfusion 
Results
In the primary analysis main-study phase population, 
the Tigertriever achieved the primary end point of suc-
cessful reperfusion (mTICI 2b-3) within 3 passes and 
without rescue therapy in 99 of 117 patients, 84.6% 
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performance goal and the 73.4% historical rate (noninfe-
riority P<0.0001; superiority P<0.01; Table 2, Figure IIB 
in the Data Supplement).
The full distribution of reperfusion outcomes is shown 
in Figure 2A. The rate of excellent reperfusion (mTICI 
2c-3) within 3 passes of the Tigertriever was 63.2% 
and 71.8% after all interventions. The frequency of first 
pass excellent reperfusion (mTICI 2c-3) was 41.4% 
and of first pass substantial reperfusion (mTICI 2b-3) 
57.8%. The mean number of passes with the Tiger-
triever was 1.8±0.9. The rates of reperfusion achieved 
with each device size (Tigertriever and Tigertriever 17) 
and in each target artery are reported in Text I in the in 
the Data Supplement.
Rescue therapy was employed in 33 of 117 (28.2%) 
main-study phase patients (frequency of other mechani-
cal thrombectomy devices, angioplasty, intraarterial 
thrombolysis, and intracranial stenting shown in Table VI 
in the Data Supplement). In 5, at the interventionalist’s 
discretion, a different device was used before reaching 3 
passes with Tigertriever. Per protocol, these were counted 
as failures despite not having not made 3 attempts with 
Tigertriever. In 13, the additional devices were used at 
interventionalist discretion to further improve reperfusion 
despite mTICI ≥2b having been attained within 3 passes 
of the Tigertriever. Per protocol, these were counted 
as Tigertriever successes in achieving mTICI≥2b Final 
reperfusion rates after all interventions were 95.7% 
mTICI 2b-3; 71.8% mTICI 2c-3; and 41.9% mTICI 3. 
Median time from arterial puncture to successful reper-
fusion (mTICI 2b-3) was 24 minutes (IQR, 16–38).
Primary efficacy end point and additional reperfusion 
results in lead-in patients did not statistically differ from 
main-study phase patient results (Table VII in the Data 
Supplement).
Primary Safety End Point
In the primary analysis main-study phase population, the 
rate for the primary safety composite end point of com-
bined sICH and 90-day all-cause mortality was 18.1% 
(95% CI, 11.1%–25.1%, Table 3), compared with the 
PG of 30.4% and historical rate of 20.4% (noninferi-
ority P=0.004; superiority P=0.57). The primary safety 
end point in lead-in patients did not statistically differ 
from main-study phase patient results (Table VIII in the 
Data Supplement).
Secondary End Points
Secondary clinical efficacy outcomes are shown in 
Table 2. In main-study phase patients, good clinical 
outcome (functional independence, mRS score 0–2) 
was attained by 58.0% (95% CI, 48.3%–67.3%), a rate 
superior to the 43.5% in the pooled comparator trials 
(P=0.006). The full distribution of disability levels at 90 
days is shown in Figure 2B. Health-related quality of life 
on the EQ-5D at 90 days was median 80 (IQR, 70–90) 
and granular disability level on the Academic Medical 
Table 1. Patient and Procedure Characteristics for Main-





Age, y; mean (SD) 65 (15) 66 (15)
Male sex, n (%) 72 (61.5%) 92 (58%)
Race, n (%)
 White 99 (84.6%) 134 (83.7%)
 Black 17 (14.5%) 24 (15%)
 Asian 1 (0.85%) 2 (1.25%)
Hispanic ethnicity, n (%) 16 (13.7%) 24 (15%)
NIHSS score
 Mean (SD) 17.4 (5.6) 17.6 (5.6)
 Median (IQR) 17 (12–21) 18 (13–22)
Baseline CT ASPECTS
 Mean (SD) 8.9 (1.1) 8.8 (1.2)
 Median (IQR) 9 (8–10) 9 (8–10)
Prestroke mRS, n (%) (n=117) (n=156)
 0–1 116 (99.2%) 155 (99.4%)
 0 93 (79.5%) 127 (81.4%)
 1 23 (19.7) 28 (17.8%)
 Body mass index, median (IQR) 29.5 (25–35) 30.4 (25.7–36.2)
Medical history, n (%)
 Hypertension 89 (76%) 126 (78.8%)
 Diabetes 36 (30.8%) 52 (32.5%)
 Atrial fibrillation 47 (40.2) 60 (37.5%)
 Dyslipidemia 57 (48.7%) 81 (50.6%)
 Previous MI/CAD 23 (19.7%) 34 (21.3%)
  Previous ischemic stroke/transient 
ischemic attack
16 (13.7%) 20 (12.5%)
 Intravenous tPA failure 77 (65.8%) 111 (69.4%)
Proximal occlusion location, n (%)
 M1 middle cerebral artery 67 (57.3%) 87 (54.4%)
 M2 middle cerebral artery 23 (19.7%) 37 (23.2%)
 Internal carotid artery 24 (20.5%) 31 (19.4%)
 Basilar 3 (2.6%) 5 (3.2%)
 Occlusion side (left) 48 (41%) 80 (50%)
  Last known well to arterial punc-






 General anesthesia 49 (41.9%) 73 (45.6%)
 BGC use only 25 (21.4%) 43 (26.9%)
 BGC+intermediate catheter use 10 (29.9%) 56 (35%)
 Intermediate catheter use only 21 (17.9%) 28 (17.5%)
ASPECTS indicates Alberta Stroke Program Early CT Score; BGC, balloon 
guide catheter; CAD, coronary artery disease; IQR, interquartile range; MI, myo-
cardial infarction; mRS, modified Rankin Scale; TIGER, Treatment With Intent to 
Generate Endovascular Reperfusion; and tPA, tissue-type plasminogen activator.
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Center Linear Disability Score at 90 days was median 
93.3 (IQR, 57.8–100).
Secondary safety outcomes are shown in Table 3. 
Neurological deterioration by 4 or more NIHSS points 
by 24 hours occurred in 7.7% (95% CI, 3.6%–14.2%). 
The rate of embolization to a previously uninvolved new 
territory was 2.6% (95% CI, 0.5%–7.4%), a rate superior 
to the 7.4% in the pooled comparator trials (P=0.0403). 
Asymptomatic intracranial hemorrhage within 24 hours 
occurred in 31.0% (95% CI, 22.7%–40.3%). (Additional 
data on radiological classification of hemorrhages are 
shown in Tables IX and X in the Data Supplement.)
Secondary clinical efficacy and safety results in lead-
in patients did not statistically differ from main-study 
phase patient results (Tables III and IV in the Data Sup-
plement). All adverse events are shown in Table XI in the 
Data Supplement.
Tigertriever Performance in Vessels of Different 
Size
Tigertriever performance in smaller (<2 mm) and larger 
(≥2 mm) vessels is shown in Table 4. Median vessel diam-
eters were 1.6 mm (IQR, 1.5–1.8) for smaller vessels and 
2.5 mm (IQR, 2.2–3.0) for larger vessels. Rates of both 
the primary efficacy end point (successful reperfusion) 
and the primary safety end point components (sICH at 
24 hours and all-cause mortality at 90 days) were com-
parable in both vessel size groups.
DISCUSSION
In this prospective, multicenter trial, the Tigertriever 
yielded high rates of reperfusion among patients with 
acute ischemic stroke swith large vessel occlusion, 
with substantial reperfusion achieved in >8 of every 
10 patients with the Tigertriever alone and >9 of every 
10 patients after additional interventions. The rate of 
successful reperfusion surpassed the predefined per-
formance goal against the predicate Trevo and Soli-
taire devices derived from regulatory registration and 
additional pivotal trials. The high successful reperfusion 
rates with the Tigertriever device translated to favorable 
functional outcomes, with nearly 6 of every 10 patients 
achieving functional independence at day 90.
Patients enrolled in the TIGER study were similar to the 
comparator studies in several key features, including age, 
presenting deficit severity (NIHSS), extent of ischemic 
injury on initial imaging (Alberta Stroke Program Early CTs), 
vascular risk factors, rate of pretreatment with tPA, and fre-
quency of target occlusion in internal carotid artery and M1 
middle cerebral artery (Table IV in the Data Supplement). 
The frequency of M2 middle cerebral artery occlusions 
was mildly higher in the present study than several com-
parator studies but lower than in the most recent compara-
tor investigation, ARISE II.20 The greater proportion of M2 
Table 2. Angiographic and Clinical Efficacy Outcomes in 




Primary efficacy end point
  Successful reperfusion 
(mTICI 2b-3 within 3 
Tigertriever passes without 
rescue), n (%)
99 (84.6%) 130 (81.3%)
(95% CI, 
78.1%–91.2%)
(95% CI,  
75.2%–87.3%)
Angiographic outcomes within 3 Tigertriever passes
  Excellent reperfusion (mTICI 
2c-3 within 3 Tigertriever 
passes without rescue), n (%)
74 (63.2%) 94 (58.8%)
 0 9 (7.7%) 17 (10.6%)
 1 2 (1.7%) 2 (1.3%)
 2a 7 (6%) 11 (6.9%)
 2b 25 (21.4%) 36 (22.5%)
 2c 28 (23.9%) 30 (18.8%)
 3 46 (39.3%) 64 (40%)
Other angiographic and procedural outcomes
  Final successful reperfusion 
(mTICI 2b-3)
112 (95.7%) 150 (93.8%)
  Final excellent reperfusion 
(mTICI 2-3c)
84 (71.8%) 106 (66.3%)
  0 3 (2.6%) 4 (2.5%)
  1 0 0
  2a 2 (1.7%) 6 (3.8%)
  2b 28 (23.9%) 44 (27.5%)
  2c 35 (29.9%) 38 (23.8%)
  3 49 (41.9%) 68 (42.5%)
  First-pass successful reperfu-
sion (mTICI 2b-3)*
67/116 (57.8%) 89/158 (56.3%)
  First-pass excellent reperfu-
sion (mTICI 2c-3)*
48/116 (41.4%) 66/158 (41.8%)
 Use of rescue therapy‡ 33 (28.2%) 51 (31.9%)
  Time from puncture to mTICI 
2b-3, median (IQR)
24 (16–38) 25 (17–43)
N=103 N=139
  Time from puncture to clo-
sure, median (IQR)†
43 (28-72.5) 48 (30-84)
Clinical outcomes
  90-d good outcome (mRS 
score 0–2), n (%) (95% CI)
65/112 (58%) 86/154 (55.8%) 
(95% CI, 
48.33%–67.29%)
(95% CI,  
47.63%–63.83%)
 EQ-5D at 90 d, median (IQR) 0.80 (0.70–0.90) 0.80 (0.68–0.90)
(N=81) (N=112)
  ALDS at 90 d, median (IQR), 
mean (SD)
93.3% (57.8-100) 93.3% (60.4–100)
77.3% (30.2%) 78.1% (30.0%)
(N=83) (N=114)
ALDS indicates Academic Medical Center Linear Disability Score; IQR, inter-
quartile range; mRS, modified Rankin Scale; and mTICI, modified Thrombolysis 
in Cerebral Ischemia.
*Angio after first pass was not available from 1 lead-in and 1 main-study 
patient.
†Closure time was not available from 1 main-study patient.
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occlusions reflects the increasing treatment of more distal 
vessel occlusions in clinical practice.21 M2 occlusions have 
features that make them both more difficult targets for 
EVT, including distal location, smaller size, reduced acces-
sibility, and less difficult, including smaller thrombus burden. 
As the frequency of reperfusion of the M2 was similar to 
other occlusion sites in the present study, the distribution 
of target occlusions did not affect comparison with prior 
studies. Patients in this study were treated sooner after 
onset (last known well to puncture 2 hour 59 minutes) 
than in prior studies, in accord with increasing emphasis in 
national guidelines and national practice on accelerating 
speed of endovascular thrombectomy.6–8
Reperfusion rates were better in the current study 
than in the comparator studies in a variety of param-
eters, including first pass reperfusion, mean number of 
passes, reperfusion after up to 3 passes before rescue 
therapy, and final reperfusion after rescue therapy. First 
pass effect, defined as achieving mTICI 2c-3 reperfusion 
with one pass of the stent retriever, is likely to yield bet-
ter patient outcomes and is a stringent metric to assess 
device performance.22 In the current study, a first pass 
effect was achieved in 41.4% of patients, which compares 
favorably to the rate of 25% in both the North American 
Solitaire Acute Stroke registry23 and Trevo acute isch-
emic stroke registry.24 In the ARISE II study, the first pass 
effect was seen in 40% of patients,20 which is compa-
rable to the present study. In the current study, successful 
reperfusion at procedure end, including rescue therapies, 
was achieved in nearly every patient (96%), a value that 
elevates cerebral reperfusion success rates to those of 
cardiac reperfusion procedures.25,26
Faster time from puncture to achievement of reper-
fusion has been associated with improved clinical 
Figure 2. Reperfusion and functional outcomes in main-study phase of TIGER trial (Treatment With Intent to Generate 
Endovascular Reperfusion).
A, Reperfusion degree after first pass, after up to 3 Tigertriever passes, and after rescue therapy. B, Distribution of 90-d global disability outcomes 
on the modified Rankin Scale (mRS). mRS was available from 114 patients out of the 117 of the main-study group. mTICI indicates modified 
Thrombolysis in Cerebral Ischemia.
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outcomes.27 The current study results demonstrate the 
median procedure time (from puncture to achievement 
of mTICI ≥2b) was 25 (IQR, 17–43) minutes, which com-
pares favorably to the ARISE II study, where the median 
time was 35 (IQR, 24–58) minutes.20 This time was 
similar to the contact aspiration first pass thrombectomy 
time of median 25 minutes as reported in the COMPASS 
study (Aspiration Thrombectomy Versus Stent Retriever 
Thrombectomy as First-Line Approach for Large Ves-
sel Occlusion) but shorter than the median 35 minutes 
reported for that trial’s stent retriever group.28 In experi-
enced, high-volume centers performing over 48 throm-
bectomies annually, the median puncture-to-reperfusion 
time with the Trevo device was 67 (IQR, 42–105) min-
utes.29 The reduced procedure times with the Tigertriever 
may reflect in part the technological advancement of the 
operator being able to adjust the radial force expansion 
to interact with the clot in a more productive manner.
The use of a BGC in the proximal vessel of the target 
occlusion when prior stent retrievers are deployed has 
been shown to improve the first pass reperfusion effect 
and clinical outcomes.30 The proximal flow arrest may 
prevent distal embolization or non- target distal embo-
lization. The unique design of the Tigertriever allows for 
more effective internalization of the thrombus into the 
interstices of the device. As the device is collapsed by 
the operator, it theoretically limits the chance of distal 
embolization as the clot is completely entwined in the 
retriever. The current study had a lower rate of BGC use 
at 35% in the intention to treat population, in comparison 
to the ARISE II trial in which this technique was used in 
73.6% of patients.20 Despite the lower use of BGC in 
this study, there were only 4 patients (2.5%) who had 
an embolization to a new territory compared with 6.6% 
in ARISE II and to 7.4% in the pooled data from of MR 
CLEAN,1 ARISE II,20 REVASCAT,3 and TREVO 2.13
Table 3. Safety End Points in Main-Study and Combined Lead-In/Main-Study Patients
TIGER
Main-study (n=117) All (n=160)
Primary safety composite end point, n (%)
  Symptomatic intracranial hemorrhage within 24 h 
and 90 d all-cause mortality*
21 (18.1%) 31/159* (19.5%)
(95% CI, 11.1%–25.1%) (95% CI, 13.3%–25.7%)
Secondary safety end points, n (%)
 Symptomatic intracranial hemorrhage within 24 h† 2 (1.7%) 3 (1.9%)
(95% CI, 0.2%–6.03%) (95% CI, 0.39%–5.38%)
 90-d all-cause mortality* 21 (18.1%) 31/159* (19.5%)
(95% CI, 11.1%–25.1%) (95% CI, 13.3%–25.7%)
 Asymptomatic intracranial hemorrhage within 24 h 36 (31.0%) 50‡ (31.4%)
(95% CI, 22.7%–40.29%) (95% CI, 24.32%–39.27%)
 Neurological deterioration within 24 h 9 (7.7%) 14 (8.8%)
(95% CI, 3.61%–14.21%) (95% CI, 4.9%–14.33%)
 Embolization to new territory 3 (2.6%) 4‡ (2.5%)
(95% CI, 0.53%–7.37%) (95% CI, 0.69%–6.31%)
CT indicates computed tomography; sICH, symptomatic intracranial hemorrhage; and TIGER, Treatment With Intent to Generate 
Endovascular Reperfusion.
*One patient withdrew consent at the day 4 visit so did not contribute full to 90-d mortality assessment.
†All sICH events occurred in cases treated with Tigertriever plus rescue therapy.
‡N=159. Reduced sample size due to missing 24 h CT or final angiogram.
Table 4. Tigertriever Performance in Vessels of Different Size Among Combined Lead-In/Main-Study 
Patients
 
Vessel diameter <2 mm 
(N=27)
Vessel diameter ≥2 mm 
(N=133) P Value
Vessel diameter, mean (SD), mm 1.58 (0.29) 2.71 (0.67) …
Vessel diameter, median (IQR; range), mm 1.6 (IQR, 1.5–1.8) 2.5 (IQR, 2.2–3) …
(Range, 0.7–1.9) (Range, 2.0–6.0)
Successful reperfusion (mTICI 2b-3) within 3 Tiger-
triever passes without rescue), n (%)
23 (85.2%) 107 (80.4%) 0.79
90-d all-cause mortality, n (%) 3 (11.1%) 28 (21.0%) 0.29
sICH at 24 h, n (%) 0 (0%) 3 (2.2%) 1.00
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Clinical outcomes in the present study were favorable. 
Functional independence (mRS score 0–2) at 90 days 
was achieved in 58% of patients, a rate higher than in 
the comparator studies. Similarly, health-related quality of 
life showed a utility value of 0.80, higher than the 0.57 
in the MR CLEAN trial.31 These high rates of good long-
term functional outcome likely reflect reduced total brain 
ischemia time because of high achieved reperfusion 
rates, early last known well-to-punctures times, and rapid 
puncture-to-reperfusion times. The faster last known 
well-to-puncture times versus historical comparator trials 
likely reflects interval evolution in endovascular workflow 
and systems of care, while the increased perfusion rates 
and rapid puncture-to-reperfusion times likely at least in 
part reflect intrinsic properties of the Tigertriever itself.
Limitations
This study has limitations. The study design was a single-
arm trial against objective performance criteria derived 
from pooled prior studies of predicate devices, rather than 
a randomized trial with a contemporaneous control group. 
This approach constrains precision in delineating how 
well the Tigertriever compares with any particular com-
parator device. Reflecting the single-arm design, the cen-
tral imaging and site clinical outcome evaluators and were 
not blinded to treatment assignment. However, for imag-
ing the use of a central core laboratory was employed to 
mitigate any resulting bias. Similarly, for clinical outcomes, 
the primary efficacy outcome was performed by certified 
raters using a structured assessment system (the Rankin 
Focused Assessment) and the congruence of rater 
assessments of global disability and patient-reported 
health-related quality of life indicates accurate scoring.
Conclusions
In this prospective, multicenter study with a unique oper-
ator-controlled stent retriever, the Tigertriever achieved 
successful reperfusion within 3 passes in >8 of every 
10 patients, demonstrating noninferiority over a perfor-
mance goal and superiority over actual historical rates 
derived from trials and prospective studies of established 
devices. In addition, first pass successful reperfusion was 
achieved in nearly 6 of every 10 patients and final suc-
cessful reperfusion in >9 of every 10 patients. Rates of 
embolization to a new territory and sICH were low and 
rates of good global disability and health-related quality 
of life outcomes high. Efficacy and safety outcomes were 
similar in vessels with diameters <2 and ≥2 mm.
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